Full-Time

Senior Source Scientist

Control electronics

Posted on 5/9/2026

Zeiss

Zeiss

1,001-5,000 employees

Manufactures high-precision optical instruments and devices

Compensation Overview

$140k - $175k/yr

+ Performance Bonus + Sales Commissions

Company Does Not Provide H1B Sponsorship

Dublin, CA, USA

In Person

Category
Electrical Engineering (2)
,
Required Skills
FPGA
Requirements
  • PhD or Master’s degree in Electrical Engineering, Physics, or related field with specialization in high voltage electronics, power systems, embedded control, or charged particle devices
  • Demonstrated experience designing or modeling high voltage power supplies, precision analog circuits, control systems, or radiation source electronics
  • Hands-on experience with prototype electronics development, test automation, HV diagnostics, and control system characterization
  • Fluency in English is required
  • Ability to work with and understand the work product of team members from all R&D-related departments, as well as Manufacturing and Marketing; exceptional communication skills to resolve technical challenges between mechanical, electrical and software engineering, advanced development, manufacturing and marketing
  • Experience with electron guns, electron-optical lenses, vacuum devices, or Xray generation strongly preferred
Responsibilities
  • Design, model, and validate high voltage power supplies, emission drivers, and beam control electronics (20–200 kV typical range)
  • Develop fast response power conditioning and filtering architectures to ensure beam stability, low ripple, and precise emission control
  • Architect fault tolerant HV systems including arc detection, soft-start strategies, protection circuits, and thermal limit handling
  • Collaborate with electrical and safety teams to ensure compliance with HV safety standards, insulation requirements, and regulatory constraints
  • Design closed loop control algorithms for electron-beam current, voltage regulation, spot stabilization, and thermal management
  • Develop embedded control firmware, FPGA/MCU logic, and diagnostic interfaces for real-time monitoring of HV subsystems
  • Integrate sensor networks (current monitors, thermal sensors, vacuum gauges, X-ray detectors) into robust, intelligent control architectures
  • Prototype advanced stabilization techniques such as active feedback loops, feed‑forward compensation, and predictive control models
  • Work with electron-optics designers to ensure HV architectures and control systems support optimal beam formation, focusing, and landing characteristics
  • Model high voltage interactions affecting electron target performance, including emission stability, energy deposition, and degradation pathways
  • Support the development of target assemblies compatible with advanced HV control schemes and high-power deposition scenarios
  • Lead the build and validation of HV electronic assemblies, control boards, interlocks, high voltage feedthroughs, and diagnostic systems
  • Conduct quantitative testing of power supply performance, stability under load, noise spectra, transient behavior, and feedback loop response
  • Collaborate with mechanical, software, and system engineering teams to ensure seamless integration of HV and control subsystems into full X-ray instruments
  • Own HV electronics and control system projects from concept through prototype demonstration, including planning, risk analysis, and reporting
  • Mentor engineers and interns in power electronics design, embedded controls, and instrumentation physics
  • Drive innovation by identifying emerging HV technologies, advanced control architectures, and strategic opportunities for differentiation
Desired Qualifications
  • Experience with electron guns, electron-optical lenses, vacuum devices, or Xray generation strongly preferred

ZEISS is a global leader in optics and optoelectronics, serving medical professionals, industrial manufacturers, consumers, and the semiconductor industry. It designs and sells high-precision optical instruments, medical devices, semiconductor manufacturing equipment, and vision care products such as corrective lenses and eye-health services. Its products rely on advanced optics and imaging technologies to deliver accurate inspection, diagnosis, and manufacturing outcomes across healthcare, industrial quality control, consumer optics, and chip fabrication. What sets ZEISS apart is its breadth and depth: a long-standing scale in multiple markets, integrated solutions across optics, imaging, metrology, and precision engineering, and a commitment to sustainability in electricity use and carbon emissions. The company’s goal is to advance optics and optoelectronics by providing reliable, high-quality tools and services worldwide while operating in a sustainable way.

Company Size

1,001-5,000

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$1.1B

Headquarters

Oberkochen, Germany

Founded

2001

Simplify Jobs

Simplify's Take

What believers are saying

  • Shop-floor metrology adoption accelerates CMM sales into automotive, aerospace, heavy equipment sectors.
  • Cloud-based Collaborative Care extends subscription licensing model to industrial quality networks.
  • MICOR 700 ultrasound-free handheld device opens portable metrology market in surgical applications.

What critics are saying

  • ASML's EUV lithography monopoly threatens ZEISS semiconductor optics segment revenue sustainability.
  • VisioGen AI platform faces FDA liability exposure if AI responses cause patient harm.
  • Ransomware attack on ZEISS Health Data Platform halts clinical workflows across customer sites.

What makes Zeiss unique

  • ZEISS dominates precision optics across semiconductor, medical, and industrial segments globally.
  • ARTEVO 850 microscope offers 60% depth-of-field increase with true 3D visualization capability.
  • VisioGen AI platform provides human-verified patient engagement integrated into ophthalmology workflows.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Zeiss who can refer or advise you

Benefits

Health Insurance

401(k) Retirement Plan

Paid Vacation

Performance Bonus

Company News

PR Newswire
Apr 2nd, 2026
ZEISS unveils AI-powered patient platform and enhanced IOL tools at ASCRS

ZEISS has unveiled new digital, AI and surgical innovations for cataract and refractive workflows at the ASCRS conference. The medical technology company is expanding its US cataract portfolio with new irrigation/aspiration handpieces compatible with the DORC EVA NEXUS surgical system, alongside enhanced IOL calculation capabilities for the ZEISS IOLMaster 700. ZEISS also launched VisioGen commercially in the US, a human-verified AI patient engagement platform for ophthalmology practices. The platform integrates with clinic websites to capture patient demand around the clock, with AI-assisted responses reviewed by ZEISS-trained optometrists before delivery. The company showcased ZEISS Collaborative Care, a cloud-based application enabling secure data sharing between eye care professionals, and previewed ZEISS CLINIC 360, pending FDA clearance. ZEISS is celebrating 100 years of US operations this year.

PR Newswire
Mar 24th, 2026
ZEISS expands ophthalmic portfolio in Canada with new diagnostic lasers and workflow tools

ZEISS Medical Technology has expanded its ophthalmic workflow portfolio in Canada with new diagnostic, visualisation and therapeutic solutions. The company will showcase the innovations at upcoming Canadian ophthalmology conferences in Ottawa and Montréal. Key additions include ICGA for ZEISS CLARUS 700, offering simultaneous FA and ICG capture for clinical assessment, and ZEISS VISULAS green with selective laser trabeculoplasty for retinal photocoagulation. The company has introduced refraction devices ZEISS VISUREF 600 and ZEISS VISUCORE 500 to streamline diagnostic workflows. ZEISS also launched VISULAS yag, a new-generation therapeutic laser for anterior segment photodisruption within cataract workflows. The ZEISS FORUM subscription package, now available in Canada, offers integrated data management with unlimited device licences and lower upfront costs.

PR Newswire
Feb 23rd, 2026
ZEISS launches Collaborative Care app for eye care professionals with cloud and on-premises options

ZEISS Medical Technology has launched Collaborative Care, a browser-based application enabling eye care professionals to share data securely, refer patients and coordinate clinical care. Built on the ZEISS Health Data Platform, the solution addresses fragmented data sharing and inefficient referral processes in ophthalmic care. The application offers flexible deployment as either a standalone cloud solution or an integrated extension of ZEISS FORUM. Key features include secure exchange of images and reports, streamlined referral workflows with tracking capabilities, and tools for building professional networks between optometrists and ophthalmologists. ZEISS Collaborative Care was demonstrated at industry events in London and Orlando in February and March 2026. The company generated €2,228 million in revenue in fiscal year 2024/25 with 5,784 employees worldwide.

Handelsblatt
Feb 19th, 2026
Custom Surgical raises $4M to develop AI-powered ophthalmology platform

Custom Surgical, a German ophthalmology company, has raised €3.5 million to advance its platform. The funding will support development of AI-powered features including automated image optimisation and assisted triage processes that help determine case urgency and specialist assignment. The company is already developing its first AI-based triage and screening system. The technology aims to provide initial assessments that guide decisions on how urgently cases need attention and which medical professionals should handle them next.

Investors Hangout
Feb 18th, 2026
Mindpeak raises $15.3M Series A to scale AI cancer diagnostic tools

Mindpeak, an AI-driven pathology startup, raised $15.3 million in a Series A round led by ZEISS Ventures and InnoVentureFund in 2024. The funding will accelerate development and deployment of the company's AI diagnostic tools for cancer pathology. Founded in 2018, Mindpeak's algorithms have supported over 30,000 patient diagnoses across US and European healthcare markets. The technology uses automated histological analyses to help pathologists make faster, more precise clinical decisions. CEO Felix Faber stated the capital would expedite product rollouts and expand capabilities. The company has established strategic partnerships with major players including Roche. Mindpeak operates in the rapidly growing digital pathology market, driven by technological innovation and increasing demand for advanced diagnostic services in an ageing population.